vs
Side-by-side financial comparison of Neptune Insurance Holdings Inc. (NP) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Neptune Insurance Holdings Inc. is the larger business by last-quarter revenue ($37.8M vs $23.0M, roughly 1.6× Intellia Therapeutics, Inc.). Neptune Insurance Holdings Inc. runs the higher net margin — 0.1% vs -416.2%, a 416.3% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 28.8%).
Neptune Insurance Holdings Inc. is a specialty insurance holding company that offers a broad portfolio of property and casualty insurance products, with a core focus on residential and commercial flood insurance for customers across the United States. It serves both individual consumers and small to mid-sized business clients, using advanced data analytics to support accurate policy pricing and robust risk management.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
NP vs NTLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.8M | $23.0M |
| Net Profit | $50.0K | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | — | -428.9% |
| Net Margin | 0.1% | -416.2% |
| Revenue YoY | 28.8% | 78.8% |
| Net Profit YoY | 0.0% | 25.7% |
| EPS (diluted) | $0.05 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $37.8M | — | ||
| Q4 25 | — | $23.0M | ||
| Q3 25 | $44.4M | $13.8M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.6M | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | $33.8M | $9.1M | ||
| Q2 24 | — | $7.0M |
| Q1 26 | $50.0K | — | ||
| Q4 25 | — | $-95.8M | ||
| Q3 25 | $11.5M | $-101.3M | ||
| Q2 25 | — | $-101.3M | ||
| Q1 25 | — | $-114.3M | ||
| Q4 24 | — | $-128.9M | ||
| Q3 24 | $12.1M | $-135.7M | ||
| Q2 24 | — | $-147.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -428.9% | ||
| Q3 25 | 46.7% | -808.9% | ||
| Q2 25 | — | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | — | -1059.9% | ||
| Q3 24 | 58.6% | -1589.0% | ||
| Q2 24 | — | -1998.6% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | -416.2% | ||
| Q3 25 | 25.9% | -735.2% | ||
| Q2 25 | — | -710.8% | ||
| Q1 25 | — | -687.6% | ||
| Q4 24 | — | -1001.2% | ||
| Q3 24 | 35.8% | -1489.5% | ||
| Q2 24 | — | -2112.6% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | — | $-0.81 | ||
| Q3 25 | $0.06 | $-0.92 | ||
| Q2 25 | — | $-0.98 | ||
| Q1 25 | — | $-1.10 | ||
| Q4 24 | — | $-1.27 | ||
| Q3 24 | $0.06 | $-1.34 | ||
| Q2 24 | — | $-1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $671.4M |
| Total Assets | — | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $449.9M | ||
| Q3 25 | $12.2M | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $247.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $671.4M | ||
| Q3 25 | $-509.5M | $748.4M | ||
| Q2 25 | — | $715.3M | ||
| Q1 25 | — | $779.9M | ||
| Q4 24 | — | $872.0M | ||
| Q3 24 | $-374.3M | $962.6M | ||
| Q2 24 | — | $971.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $842.1M | ||
| Q3 25 | $89.6M | $925.3M | ||
| Q2 25 | — | $898.9M | ||
| Q1 25 | — | $986.2M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-69.3M | ||
| Q3 25 | $38.9M | $-76.9M | ||
| Q2 25 | — | $-99.6M | ||
| Q1 25 | — | $-148.9M | ||
| Q4 24 | — | $-85.2M | ||
| Q3 24 | — | $-84.8M | ||
| Q2 24 | — | $-58.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | — | $-59.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | — | -850.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 14.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.38× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NP
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
